Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]A. S. Go, D. Mozaffarian, V. L. Roger, E. J. Benjamin et al. American Heart Association Statistics and S. Stroke Statistics: Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation, 129 (3), e28-e292 (2014)

  • [2]R. C. McLean and M. Jessup: The challenge of treating heart failure: a diverse disease affecting diverse populations. JAMA, 310 (19), 2033-4 (2013)

  • [3]C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey, Jr., M. H. Drazner, et al. American College of Cardiology and G. American Heart Association Task Force on Practice: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 62 (16), e147-239 (2013)

  • [4]M. Jessup and S. Brozena: Heart failure. N Engl J Med, 348 (20), 2007-18 (2003)

  • [5]B. Duygu, E. M. Poels and P. A. da Costa Martins: Genetics and epigenetics of arrhythmia and heart failure. Front Genet, 4, 219 (2013)

  • [6]B. E. Bernstein, A. Meissner and E. S. Lander: The mammalian epigenome. Cell, 128 (4), 669-81 (2007)

  • [7]A. V. Shirodkar and P. A. Marsden: Epigenetics in cardiovascular disease. Curr Opin Cardiol, 26 (3), 209-15 (2011)

  • [8]A. P. Feinberg: Phenotypic plasticity and the epigenetics of human disease. Nature, 447 (7143), 433-40 (2007)

  • [9]C. M. Greco and G. Condorelli: Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nat Rev Cardiol (2015)

  • [10]J. Yang, W. W. Xu and S. J. Hu: Heart Failure: Advanced Development in Genetics and Epigenetics. Biomed Res Int, 2015, 352734 (2015)

  • [11]Z. D. Smith and A. Meissner: DNA methylation: roles in mammalian development. Nat Rev Genet, 14 (3), 204-20 (2013)

  • [12]T. Jenuwein and C. D. Allis: Translating the histone code. Science, 293 (5532), 1074-80 (2001)

  • [13]C. L. Peterson and M. A. Laniel: Histones and histone modifications. Curr Biol, 14 (14), R546-51 (2004)

  • [14]J. I. Wu, J. Lessard and G. R. Crabtree: Understanding the words of chromatin regulation. Cell, 136 (2), 200-6 (2009)

  • [15]R. Marmorstein and S. Y. Roth: Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev, 11 (2), 155-61 (2001)

  • [16]A. J. de Ruijter, A. H. van Gennip, H. N. Caron, S. Kemp and A. B. van Kuilenburg: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370(Pt 3), 737-49 (2003)

  • [17]M. A. Glozak, N. Sengupta, X. Zhang and E. Seto: Acetylation and deacetylation of non-histone proteins. Gene, 363, 15-23 (2005)

  • [18]M. Dokmanovic, C. Clarke and P. A. Marks: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res, 5 (10), 981-9 (2007)

  • [19]P. Gallinari, S. Di Marco, P. Jones, M. Pallaoro and C. Steinkuhler: HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res, 17 (3), 195-211 (2007)

  • [20]T. Kouzarides: Histone methylation in transcriptional control. Curr Opin Genet Dev, 12 (2), 198-209 (2002)

  • [21]R. Teperino, K. Schoonjans and J. Auwerx: Histone methyl transferases and demethylases; can they link metabolism and transcription? Cell Metab, 12 (4), 321-7 (2010)

  • [22]P. A. Cloos, J. Christensen, K. Agger and K. Helin: Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev, 22 (9), 1115-40 (2008)

  • [23]J. W. Hojfeldt, K. Agger and K. Helin: Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov, 12 (12), 917-30 (2013)

  • [24]S. Djebali, C. A. Davis, A. Merkel, A. Dobin, T. et al. Gingeras: Landscape of transcription in human cells. Nature, 489 (7414), 101-8 (2012)

  • [25]H. Ling, M. Fabbri and G. A. Calin: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov, 12 (11), 847-65 (2013)

  • [26]K. C. Wang and H. Y. Chang: Molecular mechanisms of long noncoding RNAs. Mol Cell, 43 (6), 904-14 (2011)

  • [27]S. Uchida and S. Dimmeler: Long noncoding RNAs in cardiovascular diseases. Circ Res, 116 (4), 737-50 (2015)

  • [28]J. Krol, I. Loedige and W. Filipowicz: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet, 11 (9), 597-610 (2010)

  • [29]R. C. Lee, R. L. Feinbaum and V. Ambros: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75 (5), 843-54 (1993)

  • [30]A. Kozomara and S. Griffiths-Jones: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res, 39(Database issue), D152-7 (2011)

  • [31]E. Huntzinger and E. Izaurralde: Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet, 12 (2), 99-110 (2011)

  • [32]M. J. Kye and C. Goncalves Ido: The role of miRNA in motor neuron disease. Front Cell Neurosci, 8, 15(2014)

  • [33]C. J. Brown, B. D. Hendrich, J. L. Rupert, R. G. Lafreniere, Y. Xing, et al: The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell, 71 (3), 527-42 (1992)

  • [34]M. Guttman and J. L. Rinn: Modular regulatory principles of large non-coding RNAs. Nature, 482 (7385), 339-46 (2012)

  • [35]L. Ma, V. B. Bajic and Z. Zhang: On the classification of long non-coding RNAs. RNA Biol, 10 (6), 925-33 (2013)

  • [36]E. A. Gibb, C. J. Brown and W. L. Lam: The functional role of long non-coding RNA in human carcinomas. Mol Cancer, 10, 38 (2011)

  • [37]M. V. Latronico and G. Condorelli: Therapeutic applications of noncoding RNAs. Curr Opin Cardiol, 30 (3), 213-21 (2015)

  • [38]P. J. Batista and H. Y. Chang: Long noncoding RNAs: cellular address codes in development and disease. Cell, 152 (6), 1298-307 (2013)

  • [39]J. L. Rinn, M. Kertesz, J. K. Wang, S. L. Squazzo, X. Xu, et al: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell, 129 (7), 1311-23 (2007)

  • [40]M. Huarte, M. Guttman, D. Feldser, M. Garber, et al: A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell, 142 (3), 409-19 (2010)

  • [41]T. Hung, Y. Wang, M. F. Lin, A. K. Koegel, et al. Wong and H. Y. Chang: Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet, 43 (7), 621-9 (2011)

  • [42]R. A. Gupta, N. Shah, K. C. Wang, J. Kim, H. M. Horlings, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 464 (7291), 1071-6 (2010)

  • [43]Y. Kotake, T. Nakagawa, K. Kitagawa, S. Suzuki, N. Liu, M. Kitagawa and Y. Xiong: Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene, 30 (16), 1956-62 (2011)

  • [44]K. L. Yap, S. Li, A. M. Munoz-Cabello, S. Raguz, L. Zeng, et al: Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell, 38 (5), 662-74 (2010)

  • [45]Y. Bergman and H. Cedar: DNA methylation dynamics in health and disease. Nat Struct Mol Biol, 20 (3), 274-81 (2013)

  • [46]M. T. McCabe, J. C. Brandes and P. M. Vertino: Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res, 15 (12), 3927-37 (2009)

  • [47]S. Gopalakrishnan, B. O. Van Emburgh and K. D. Robertson: DNA methylation in development and human disease. Mutat Res, 647 (1-2), 30-8 (2008)

  • [48]K. D. Robertson: DNA methylation and human disease. Nat Rev Genet, 6 (8), 597-610 (2005)

  • [49]M. Movassagh, M. K. Choy, D. A. Knowles, L. Cordeddu, et al: Distinct epigenomic features in end-stage failing human hearts. Circulation, 124 (22), 2411-22 (2011)

  • [50]M. Movassagh, A. Vujic and R. Foo: Genome-wide DNA methylation in human heart failure. Epigenomics, 3 (1), 103-9 (2011)

  • [51]S. Haider, L. Cordeddu, E. Robinson, M. Movassagh, L. Siggens, et al: The landscape of DNA repeat elements in human heart failure. Genome Biol, 13 (10), R90 (2012)

  • [52]M. Movassagh, M. K. Choy, M. Goddard, M. R. Bennett, T. A. Down and R. S. Foo: Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One, 5 (1), e8564 (2010)

  • [53]J. Haas, K. S. Frese, Y. J. Park, A. Keller, B. Vogel, A. M. Lindroth, et al: Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med, 5 (3), 413-29 (2013)

  • [54]Y. H. Kao, Y. C. Chen, C. C. Cheng, T. I. Lee, et al: Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med, 38 (1), 217-22 (2010)

  • [55]Y. H. Kao, C. C. Cheng, Y. C. Chen, C. C. Chung, et al: Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes. Lab Invest, 91 (9), 1291-7 (2011)

  • [56]T. G. Nuhrenberg, N. Hammann, T. Schnick, S. Preissl, A. Witten, et al: Cardiac Myocyte De Novo DNA Methyltransferases 3a/3b Are Dispensable for Cardiac Function and Remodeling after Chronic Pressure Overload in Mice. PLoS One, 10 (6), e0131019 (2015)

  • [57]H. Tao, J. J. Yang, Z. W. Chen, S. S. Xu, X. Zhou, et al: DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology, 323, 42-50 (2014)

  • [58]A. Vujic, E. L. Robinson, M. Ito, S. Haider, M. Ackers-Johnson, et al: Experimental heart failure modelled by the cardiomyocyte-specific loss of an epigenome modifier, DNMT3B. J Mol Cell Cardiol, 82, 174-83 (2015)

  • [59]S. Turdi, W. Sun, Y. Tan, X. Yang, L. Cai and J. Ren: Inhibition of DNA methylation attenuates low-dose cadmium-induced cardiac contractile and intracellular Ca (2+) anomalies. Clin Exp Pharmacol Physiol, 40 (10), 706-12 (2013)Doi not found.

  • [60]D. Xiao, C. Dasgupta, M. Chen, K. Zhang, et al: Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res, 101 (3), 373-82 (2014)

  • [61]Y. H. Kao, G. S. Lien, T. F. Chao and Y. J. Chen: DNA methylation inhibition: a novel therapeutic strategy for heart failure. Int J Cardiol, 176 (1), 232-3 (2014)

  • [62]S. Chang, T. A. McKinsey, C. L. Zhang, J. A. Richardson, et al: Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol, 24 (19), 8467-76 (2004)

  • [63]C. L. Zhang, T. A. McKinsey, S. Chang, C. L. Antos, et al: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 110 (4), 479-88 (2002)

  • [64]T. Zhang, M. Kohlhaas, J. Backs, S. Mishra, W. Phillips, et al: CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem, 282 (48), 35078-87 (2007)

  • [65]S. Matsushima, J. Kuroda, T. Ago, P. Zhai, J. Y. Park, et al: Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res, 112 (4), 651-63 (2013)

  • [66]T. Ago, T. Liu, P. Zhai, W. Chen, H. Li, J. D. Molkentin, et al: A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell, 133 (6), 978-93 (2008)

  • [67]C. M. Trivedi, Y. Luo, Z. Yin, M. Zhang, W. Zhu, T. Wang, T. Floss, M. Goettlicher, et al: Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med, 13 (3), 324-31 (2007)

  • [68]V. B. Pillai, N. R. Sundaresan, G. Kim, M. Gupta, S. B. Rajamohan, J. B. Pillai, et al: Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem, 285 (5), 3133-44 (2010)

  • [69]T. M. Lu, J. Y. Tsai, Y. C. Chen, C. Y. Huang, H. L. Hsu, et al: Downregulation of Sirt1 as aging change in advanced heart failure. J Biomed Sci, 21, 57 (2014)

  • [70]M. Ott and E. Verdin: HAT trick: p300, small molecule, inhibitor. Chem Biol, 17 (5), 417-8 (2010)

  • [71]R. J. Gusterson, E. Jazrawi, I. M. Adcock and D. S. Latchman: The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem, 278 (9), 6838-47 (2003)

  • [72]T. Yanazume, K. Hasegawa, T. Morimoto, T. Kawamura, H. Wada, A. Matsumori, et al: Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol, 23 (10), 3593-606 (2003)

  • [73]S. Miyamoto, T. Kawamura, T. Morimoto, K. Ono, H. Wada, Y. Kawase, et al: Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation, 113 (5), 679-90 (2006)

  • [74]Y. Sunagawa, T. Morimoto, T. Takaya, S. Kaichi, H. Wada, T. Kawamura, et al: Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J Biol Chem, 285 (13), 9556-68 (2010)

  • [75]J. Q. Wei, L. A. Shehadeh, J. M. Mitrani, M. Pessanha, T. I. Slepak, et al: Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation, 118 (9), 934-46 (2008)

  • [76]W. Qiao, W. Zhang, Y. Gai, L. Zhao and J. Fan: The histone acetyltransferase MOF overexpression blunts cardiac hypertrophy by targeting ROS in mice. Biochem Biophys Res Commun, 448 (4), 379-84 (2014)

  • [77]R. Kaneda, S. Takada, Y. Yamashita, Y. L. Choi, M. Nonaka-Sarukawa, et al: Genome-wide histone methylation profile for heart failure. Genes Cells, 14 (1), 69-77 (2009)

  • [78]G. Majumdar, I. M. Johnson, S. Kale and R. Raghow: Epigenetic regulation of cardiac muscle-specific genes in H9c2 cells by Interleukin-18 and histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide. Mol Cell Biochem, 312 (1-2), 47-60 (2008)

  • [79]A. J. Bingham, L. Ooi, L. Kozera, E. White and I. C. Wood: The repressor element 1-silencing transcription factor regulates heart-specific gene expression using multiple chromatin-modifying complexes. Mol Cell Biol, 27 (11), 4082-92 (2007)

  • [80]X. Chen, F. Niroomand, Z. Liu, A. Zankl, H. A. Katus, L. Jahn and C. P. Tiefenbacher: Expression of nitric oxide related enzymes in coronary heart disease. Basic Res Cardiol, 101 (4), 346-53 (2006)

  • [81]A. B. Stein, T. A. Jones, T. J. Herron, S. R. Patel, S. M. Day, et al: Loss of H3K4 methylation destabilizes gene expression patterns and physiological functions in adult murine cardiomyocytes. J Clin Invest, 121 (7), 2641-50 (2011)

  • [82]Q. J. Zhang, H. Z. Chen, L. Wang, D. P. Liu, J. A. Hill and Z. P. Liu: The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest, 121 (6), 2447-56 (2011)

  • [83]J. A. Wamstad, J. M. Alexander, R. M. Truty, A. Shrikumar, F. Li, K. E. Eilertson, et al: Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. Cell, 151 (1), 206-20 (2012)

  • [84]E. van Rooij, L. B. Sutherland, N. Liu, A. H. Williams, J. McAnally, et al: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A, 103 (48), 18255-60 (2006)

  • [85]M. Lagos-Quintana, R. Rauhut, A. Yalcin, J. Meyer, W. Lendeckel and T. Tuschl: Identification of tissue-specific microRNAs from mouse. Curr Biol, 12 (9), 735-9 (2002)

  • [86]Y. Zhao, J. F. Ransom, A. Li, V. Vedantham, M. von Drehle, A. N. Muth, et al: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell, 129 (2), 303-17 (2007)

  • [87]D. Sayed, C. Hong, I. Y. Chen, J. Lypowy and M. Abdellatif: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res, 100 (3), 416-24 (2007)

  • [88]I. Karakikes, A. H. Chaanine, S. Kang, B. N. Mukete, D. Jeong, S. Zhang, R. J. Hajjar and D. Lebeche: Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc, 2 (2), e000078 (2013)

  • [89]L. Elia, R. Contu, M. Quintavalle, F. Varrone, C. Chimenti, et al: Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation, 120 (23), 2377-85 (2009)

  • [90]S. Ikeda, A. He, S. W. Kong, J. Lu, R. Bejar, N. Bodyak, K. H. Lee, Q. Ma, et al: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol, 29 (8), 2193-204 (2009)

  • [91]Q. Li, X. W. Song, J. Zou, G. K. Wang, E. Kremneva, X. Q. Li, N. Zhu, et al: Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci, 123 (Pt 14), 2444-52 (2010)

  • [92]J. J. McCarthy and K. A. Esser: MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol (1985), 102 (1), 306-13 (2007)

  • [93]A. Care, D. Catalucci, F. Felicetti, D. Bonci, A. Addario, et al: MicroRNA-133 controls cardiac hypertrophy. Nat Med, 13 (5), 613-8 (2007)

  • [94]E. Bostjancic, N. Zidar, D. Stajer and D. Glavac: MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology, 115 (3), 163-9 (2010)

  • [95]R. S. Nagalingam, N. R. Sundaresan, M. P. Gupta, D. L. Geenen, R. J. Solaro and M. Gupta: A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J Biol Chem, 288 (16), 11216-32 (2013)

  • [96]I. Knezevic, A. Patel, N. R. Sundaresan, M. P. Gupta, R. J. Solaro, R. S. Nagalingam and M. Gupta: A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J Biol Chem, 287 (16), 12913-26 (2012)

  • [97]J. Ganesan, D. Ramanujam, Y. Sassi, A. Ahles, C. Jentzsch, et al: MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation, 127 (21), 2097-106 (2013)

  • [98]H. Chen, G. M. Untiveros, L. A. McKee, J. Perez, J. Li, P. B. Antin and J. P. Konhilas: Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25. PLoS One, 7 (7), e41574 (2012)

  • [99]X. Y. You, J. H. Huang, B. Liu, S. J. Liu, et al: HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochemistry (Mosc), 79 (6), 538-44 (2014)

  • [100]S. J. Matkovich, Y. Hu, W. H. Eschenbacher, L. E. Dorn and G. W. Dorn, 2nd: Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res, 111 (5), 521-31 (2012)

  • [101]G. W. Dorn, 2nd, S. J. Matkovich, W. H. Eschenbacher and Y. Zhang: A human 3’ miR-499 mutation alters cardiac mRNA targeting and function. Circ Res, 110 (7), 958-67 (2012)

  • [102]E. van Rooij, L. B. Sutherland, X. Qi, J. A. Richardson, J. Hill and E. N. Olson: Control of stress-dependent cardiac growth and gene expression by a microRNA. Science, 316 (5824), 575-9 (2007)

  • [103]T. E. Callis, K. Pandya, H. Y. Seok, R. H. Tang, et al. Wang: MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest, 119 (9), 2772-86 (2009)

  • [104]R. L. Montgomery, T. G. Hullinger, H. M. Semus, B. A. Dickinson, et al: Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation, 124 (14), 1537-47 (2011)

  • [105]B. W. Wang, G. J. Wu, W. P. Cheng and K. G. Shyu: Mechanical stretch via transforming growth factor-beta1 activates microRNA-208a to regulate hypertrophy in cultured rat cardiac myocytes. J Formos Med Assoc, 112 (10), 635-43 (2013)

  • [106]P. A. da Costa Martins, K. Salic, M. M. Gladka, et al:MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol, 12 (12), 1220-7 (2010)

  • [107]C. Bang, S. Batkai, S. Dangwal, S. K. Gupta, A. Foinquinos, A. Holzmann, et al: Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest, 124 (5), 2136-46 (2014)

  • [108]C. Wahlquist, D. Jeong, A. Rojas-Munoz, C. Kho, et al: Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature, 508 (7497), 531-5 (2014)

  • [109]E. Dirkx, M. M. Gladka, L. E. Philippen, A. S. Armand, et al: Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol, 15 (11), 1282-93 (2013)

  • [110]P. Grote, L. Wittler, D. Hendrix, F. Koch, S. Wahrisch, et al. Herrmann: The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell, 24 (2), 206-14 (2013)

  • [111]C. A. Klattenhoff, J. C. Scheuermann, L. E. Surface, R. K. Bradley, et al: Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell, 152 (3), 570-83 (2013)

  • [112]N. Ishii, K. Ozaki, H. Sato, H. Mizuno, S. Saito, A. Takahashi, et al: Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet, 51 (12), 1087-99 (2006)

  • [113]J. H. Lee, C. Gao, G. Peng, C. Greer, et al: Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res, 109 (12), 1332-41 (2011)

  • [114]L. Korostowski, N. Sedlak and N. Engel: The Kcnq1ot1 long non-coding RNA affects chromatin conformation and expression of Kcnq1, but does not regulate its imprinting in the developing heart. PLoS Genet, 8 (9), e1002956 (2012)

  • [115]P. Han, W. Li, C. H. Lin, J. Yang, C. Shang, S. T. Nurnberg, K. K. Jin, et al: A long noncoding RNA protects the heart from pathological hypertrophy. Nature, 514 (7520), 102-6 (2014)

  • [116]K. Wang, F. Liu, L. Y. Zhou, B. Long, S. M. Yuan, et al: The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res, 114 (9), 1377-88 (2014)

  • [117]K. Wang, C. Y. Liu, L. Y. Zhou, J. X. Wang, M: APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun 6, 6779 (2015)

  • [118]H. Schwarzenbach, D. S. Hoon and K. Pantel:PanTel: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 11 (6), 426-37 (2011)

  • [119]V. Oliveira-Carvalho, V. O. Carvalho, M. M. Silva, G. V. Guimaraes and E. A. Bocchi: MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure? Arq Bras Cardiol, 98 (4), 362-9 (2012)

  • [120]A. G. Seto and E. van Rooij: Circulating microRNAs to identify human heart failure. Eur J Heart Fail, 14 (2), 118-9 (2012)

  • [121]S. Matsumoto, Y. Sakata, S. Suna, D. Nakatani, M. Usami, M. Hara, T. Kitamura: Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res, 113 (3), 322-6 (2013)

  • [122]K. L. Ellis, V. A. Cameron, R. W. Troughton, C. M. Frampton: Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail, 15 (10), 1138-47 (2013)

  • [123]K. Endo, Y. Naito, X. Ji, M. Nakanishi, T. Noguchi: MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull, 36 (1), 48-54 (2013)

  • [124]L. Qiang, L. Hong, W. Ningfu, C. Huaihong and W. Jing: Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol, 168 (3), 2082-8 (2013)

  • [125]F. Varrone, B. Gargano, P. Carullo, D. Di Silvestre, A. De Palma: The circulating level of FABP3 is an indirect biomarker of microRNA-1. J Am Coll Cardiol, 61 (1), 88-95 (2013)

  • [126]H. A. Cakmak, E. Coskunpinar, B. Ikitimur, H. A. Barman, B. Karadag, N. O. Tiryakioglu, et al: The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study. J Cardiovasc Med (Hagerstown), 16 (6), 431-7 (2015)

  • [127]L. L. Wong, A. Armugam, S. Sepramaniam, D. S. Karolina, K. Y. Lim: Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail, 17 (4), 393-404 (2015)

  • [128]B. A. Dickinson, H. M. Semus, R. L. Montgomery, C. Stack, P. A. Latimer, et al: Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail, 15 (6), 650-9 (2013)

  • [129]R. Marfella, C. Di Filippo, N. Potenza, C. Sardu, M. R. Rizzo, et al: Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail, 15 (11), 1277-88 (2013)

  • [130]R. Fatima, V. S. Akhade, D. Pal and S. M. Rao: Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther, 3, 5(2015)

  • [131]R. Kumarswamy, C. Bauters, I. Volkmann, F. Maury, et al: Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res, 114 (10), 1569-75 (2014)

  • [132]H. L. Li, C. Liu, G. de Couto, M. Ouzounian, M. Sun, et al: Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest, 118 (3), 879-93 (2008)

  • [133]T. Morimoto, Y. Sunagawa, T. Kawamura, T. Takaya, et al: The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest, 118 (3), 868-78 (2008)

  • [134]Y. Sunagawa, T. Morimoto, H. Wada, T. Takaya, Y. Katanasaka, et al: A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J, 75 (9), 2151-9 (2011)

  • [135]Y. H. Kao, J. P. Liou, C. C. Chung, G. S. Lien, C. C. Kuo, S. A. Chen and Y. J. Chen: Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol, 168 (4), 4178-83 (2013)

  • [136]H. F. Nural-Guvener, L. Zakharova, J. Nimlos, S. Popovic, D. Mastroeni and M. A. Gaballa: HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair, 7, 10 (2014)

  • [137]B. S. Ferguson, B. C. Harrison, M. Y. Jeong, B. G. Reid, M. F. Wempe, F. F. Wagner, E. B. Holson and T. A. McKinsey: Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A, 110 (24), 9806-11 (2013)

  • [138]H. Kook, J. J. Lepore, A. D. Gitler, M. M. Lu, W. Wing-Man Yung, et al: Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest, 112 (6), 863-71 (2003)

  • [139]H. J. Kee, I. S. Sohn, K. I. Nam, J. E. Park, Y. R. Qian, Z. Yin, et al. Epstein and H. Kook: Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation, 113 (1), 51-9 (2006)

  • [140]M. P. Gupta, S. A. Samant, S. H. Smith and S. G. Shroff: HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. J Biol Chem, 283 (15), 10135-46 (2008)

  • [141]T. Thum, C. Gross, J. Fiedler, T. Fischer, S. Kissler, M. Bussen, P. Galuppo, et al: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456 (7224), 980-4 (2008)

  • [142]A. Castaldi, T. Zaglia, V. Di Mauro, P. Carullo, G. Viggiani, et al: MicroRNA-133 modulates the beta1-adrenergic receptor transduction cascade. Circ Res, 115 (2), 273-83 (2014)

  • [143]R. Papait and G. Condorelli: Epigenetics in heart failure. Ann N Y Acad Sci, 1188, 159-64 (2010)

  • [144]J. C. Burnett and J. J. Rossi: RNA-based therapeutics: current progress and future prospects. Chem Biol, 19 (1), 60-71 (2012)

  • [145]M. D. Xu, P. Qi and X. Du: Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Mod Pathol, 27 (10), 1310-20 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review

New insights into epigenetic modifications in heart failure

Yongming Li 1, Wei Du 1, Ruiping Zhao 1,*, Jiang Hu 2, Hongyu Li 1, Ruijuan Han 1, Qiang Yue 1, Rina Wu 1, Wei Li 1, Jinbo Zhao 1
Affiliations
Article Info

1 Department of Cardiology, Baotou Central Hospital, Baotou, China

2 Department of Surgery, Baotou Central Hospital, Baotou, China

Abstract

Heart failure (HF) is a complex syndrome that occurs when the heart is unable to take in and/or eject sufficient blood to meet the needs. HF is generally accompanied by hypertrophic changes of cardiac myocytes, the hallmark of HF. At the molecular level, these changes in cardiomyocyte phenotypes are linked to reprogramming of gene expression. Therefore, understanding the molecular mechanisms involved in these gene expression changes in HF could allow for the development of new therapies for this pathology. One mechanism of gene expression regulation that attracts attention is epigenetic modifications, including DNA methylation, histone methylation and acetylation, microRNA, and long noncoding RNA. In this review, we will discuss diverse functions of these epigenetic modifications in HF, and highlight growing evidence for the important roles of epigenetic changes acting as biomarkers for early diagnosis and prognosis of HF, or even as therapeutic targets in HF.

Keywords

  • Heart Failure
  • Cardiac Hypertrophy
  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • miRNA
  • lncRNA
  • Review

References